Spironolactone form I melts at about 70 degrees lower than form II, which is very unusual for two co-existing polymorphs. The phase relationships involving this unprecedented case of dimorphism have been investigated by constructing a topological pressure-temperature phase diagram. The transition from polymorph I to polymorph II is unambiguously exothermic while it is accompanied with an increase in the specific volume. This indicates that the dP/dT slope of the I-II equilibrium curve is negative. The convergence of the melting equilibrium lines at high pressure leads to a topological P-T diagram in which polymorph I possesses a stable phase region at high pressure. Thus, forms I and II are monotropically related at ordinary pressure and turn to an enantiotropic relationship at high pressure. Given that polymorph I is the densest form, it negates the rule of thumb that the densest form is also the most stable form at room temperature, similar to the case of paracetamol.
Introduction

The exceptional difference between the melting points of the two polymorphs of spironolactone
Most crystalline polymorphs of molecular compounds possess melting points that differ from each other by only a few degrees. Differences of more than fifty degrees are very rare, as can be inferred from a compilation of 103 sets of polymorphic systems involving "pharmaceuticals and other molecular compounds" by Burger and Ramberger (Burger and Ramberger, 1979b) in addition to more recent cases, which have been compiled in Table 1 . In Fig. 1 , it is shown that about 56% of these systems exhibit differences between their melting temperatures smaller than 10 K, and only fifteen cases (≈5%) exhibit differences higher than 40 K, which on closer scrutiny occurs mainly between the more stable polymorph and a polymorph ranking fourth or fifth in metastability.
The dimorphic system involving the orthorhombic forms of spironolactone, form I (Dideberg and Dupont, 1972) and form II (Agafonov et al., 1989) , appears to exhibit a difference of more than 70 degrees in their melting temperatures, making it therefore an exceptionally uncommon case of crystalline polymorphism . Form I melts and recrystallizes into form II in the temperature interval of 373-393 K. Form II, however, only melts at 480-483 K.
With such a large difference in melting points, it is rather puzzling why form I appears at all and the question arises whether form I has a stable domain in the pressure-temperature phase diagram, either at low temperature or at high pressure. For high-pressure measurements, a special analyzer developed in-house in the UPC (Barcelona) would have been a useful tool, however, the melting point of form II falls outside of its temperature range and the signals of the other transitions are too weak to be observed with sufficient precision. Therefore, using calorimetric and crystallographic data available in the literature and new experimental results obtained under ordinary pressure 1 , a topological pressure-temperature phase diagram has been constructed involving spironolactone polymorphs I and II and its liquid phase.
Table 1
Melting point differences between polymorphs of the same compound since the publication of Burger and Ramberger (Burger and Ramberger, 1979b Park et al. (2013) (continued on next page) infrared spectroscopic measurements (Mesley and Johnson, 1965) . In 1972, the crystal structure of a polymorph grown from an acetone solution was solved and thus called form I (Dideberg and Dupont, 1972) . With differential scanning calorimetry (DSC), it was observed that spironolactone crystallized from ethanol or from water exhibited a small exothermic peak at about 433 K and an endothermic peak at about 483 K, whereas spironolactone crystallized from methanol exhibited an endothermic peak at about 393 K followed by an exothermic peak at about 413 K (Sutter and Lau, 1975) . These and other literature data have been compiled in Table 2 . Below follows a summary description of the findings in the literature. In 1976, Florence and Salole demonstrated that pre-melting behavior observed by DSC was radically altered by grinding. They subjected a commercial specimen to differential thermal analysis (DTA) at a 10 K min −1 heating rate and recorded an endothermic peak (onset at about 423 K) followed by an exothermic peak (onset at about 433 K) and a melting peak at about 483 K (Florence and Salole, 1976) . Unfortunately, no X-ray data was reported, making it difficult to link the observed thermal behavior to a specific polymorph. In the 1980s, further investigations into the solid state of spironolactone were carried out confirming the existence of multiple polymorphs in addition to a number of solvates (Eldalsh et al., 1983; Salole and Alsarraj, 1985a,b) . In the early 1990s, the polymorphism of spironolactone and its Fig. 1 . Number of polymorph pairs as a function of the temperature difference (ΔT) between the melting temperature of the most stable polymorph and a metastable one compiled by Burger and Ramberger in yellow (Burger and Ramberger, 1979b ) and more recent data in blue (see also Table 1 ). ΔT is smaller than 15 K for 75% of the pairs and only 2 pairs (less than 1%) exhibit a difference of more than 80°C in melting points. The melting difference of spironolactone is marked in red.
solvation was revisited by Agafonov et al. (Agafonov et al., 1991a; Agafonov et al., 1991b) , who previously had solved the crystal structure of a second polymorph (thus named form II) using crystals grown from an acetone solution (Agafonov et al., 1989) . Berbenni et al. found melting temperatures ranging from 480 to 486 K and melting enthalpies from 44 to 54 J g −1 obtained from four solvent-free samples; however, their different X-ray powder diffraction patterns were not indexed and the samples were listed as polymorphs 'M', 'EV', 'E' and 'A', respectively (Berbenni et al., 1999) . Moreover, Berbenni et al. and Marini et al. reported that spironolactone decomposes in the melt (Berbenni et al., 1999; Marini et al., 2001) , which obviously may affect the values of the melting enthalpies and the melting point of form II. In 2003, high resolution X-ray powder diffraction experiments as a function of temperature demonstrated that form II exhibits no structural change up to its fusion, whereas form I transforms into form II in the 373-398 K temperature interval (Liebenberg et al., 2003) . In 2007, a I → II transformation was observed with an onset in the 373-393 K temperature interval and with a liquid as an intermediate phase, which was interpreted as a melting recrystallization . Summing over the complete endo-exothermic effect resulted in a value of 0 ± 2 J g −1 for the enthalpy of the I → II transition at the temperature of fusion of form I leaving the relative enthalpy ranking between the two phases undetermined . The melting enthalpy of form II, Δ II→L H = 55 J g −1 at 480 K (onset), was found to be close to previous values. In addition, specific volumes of forms I, v I , and II, v II , were determined as a function of temperature in the range from room temperature up to their respective melting points . At 300 K, those equations lead to the specific volumes v I (300 K) = 0.78942 cm 3 g −1 and v II (300 K) = 0.80099 cm 3 g −1 , which clearly demonstrates that form I is denser than form II. Fukuoka et al. in 1991 found a glass transition for spironolactone at T g = 331 K (Fukuoka et al., 1991) , rather different from the value of 364 K reported by Mahlin and Bergström in 2013 (Mahlin and Bergstrom, 2013) . There is no doubt that the phase behavior of spironolactone is challenging to study and except for the melting of form II uncertainty exists about the rest of its phase behavior. Seventy degrees of difference appears to exist between the melting temperatures of forms I and II and still form I can be easily obtained experimentally. Moreover, as can be judged from the specific volumes, form I is the densest polymorph and clearly less stable than form II; this is in obvious contradiction with the density rule proposed by Burger and Ramberger (Burger and Ramberger, 1979a,b) . In the present paper an attempt will be made to shine some light on the phase behavior of spironolactone by constructing a pressure-temperature phase diagram. Most likely, the last word is not written about the exact calorimetric data of the phase behavior of spironolactone, but using data from the literature and additional measurements, it will be shown that despite the 70 degrees of difference in melting points, form I does possess a stable domain in the pressure-temperature phase diagram.
Material and methods
Sample of forms I and II
Samples of medicinal grade from Sanofi (France) and from Welding GMBH (Germany), purity > 99%, were respectively found to consist of pure form II and pure form I by X-ray diffraction and used as such. In addition, crystals of form I were grown by evaporating solutions of form II in ethanol at room temperature, in accordance with the method described previously . A thermogravimetric curve of the latter form I has been provided in the supplementary materials, Fig.  S2 .
High-resolution X-ray powder diffraction
High-resolution X-ray diffraction patterns were recorded at room temperature with cylindrical position-sensitive detectors (CPS120) from INEL (France) using monochromatic Cu-Kα 1 (λ = 1.54061 Å) radiation. Fig. 2 demonstrates that the experimental diffraction patterns exhibit no differences with the respective calculated patterns based on the crystal structures.
Differential scanning calorimetry
Temperatures and heats of fusion were determined at various heating rates with a TA-Instruments Q100 thermal analyzer. Indium (T fusion = 429.75 K, Δ fusion H = 28.45 J g −1 ) was used as a standard for temperature and enthalpy calibration. Specific heat capacities as a function temperature were determined with the TA-Instruments Q100 using a modulated signal by superimposing a sinusoidal temperature change on the linear temperature increase. The linear heating rate was 2 K min −1 while the superimposed sinusoidal had an amplitude of ± 0.5 K and a period of 60 s. Vitreous spironolactone was obtained after heating specimens at 100 K min −1 up to 490 K and quenching them to room temperature within a few seconds to avoid decomposition. The so-obtained colorless 408 ± 3 −4.3 ± 4.0 479.6 ± 0.6 54.0 ± 1.5 a The commercial form is form II, form I was prepared by evaporating an ethanol solution at room temperature. b The onset of the first transition peak in the Sanofi sample is related to the melting of form I, see Fig. 3 for clarification. c The overall enthalpy of the first transformation in the Sanofi sample is related to the combined conversion of form I into liquid and its recrystallization into form II, see Fig. 3 for clarification. I.B. Rietveld et al. International Journal of Pharmaceutics 552 (2018) 193-205 transparent glass was ground into a powder and subjected to modulated DSC experiments from 220 K to 430 K. Samples were weighed using a microbalance sensitive to 0.01 mg and sealed in aluminum pans.
Results
Calorimetric data
For comparison with the melting data from the literature (Table 2) , DSC measurements with 15 separate samples of form II were carried out (Table 3) demonstrating that the present sample of form II melts at 479.6 ± 0.6 K with a melting enthalpy of Δ II→L H = 54.0 ± 1.5 J g , respectively, in reference . Form I was obtained from the Sanofi batch by evaporating an ethanol solution and its transformation behavior is represented by curve 3 in Fig. 3 . Part 'a' of the convoluted phenomenon 'ab' is the onset of the melting of form I, however, it is taken over half way by the recrystallization of form II (part 'b'). This behavior has been reported previously in the literature, however at that time it could not be determined whether the I → II transformation had a positive or a negative enthalpy . In the present case, summation over the endo-exothermic effect (peaks 'a' and 'b' in Fig. 3 ) results in Δ I→II H values ranging from +2.1 to −11.7 J g −1 depending on the run and the mean over 7 values is −4.3 ± 4.0 J g −1 with all enthalpy values except for one being negative (Table 3 ). The mean onset temperature of fusion of form I, peak 'a', is T I→L = 408 ± 3 K (see Table 3 ). Whereas form I of the spironolactone batch from Sanofi consistently melted before recrystallization into form II, form I from Welding exhibited a single exothermic peak with a mean enthalpy change of −6.9 ± 0.3 J g −1 and at a mean temperature of 375 ± 3 K (see curve 2 in Fig. 3 and Table 4 ). The single exothermic peak represents a direct transformation of form I into form II and confirms beyond doubt (Δ I→II H = −6.9 ± 0.3 J g −1 ) that the transition of form I into form II has a negative enthalpy change. The glass transition temperature T g was found to be at 306 K in the present series of experiments, as can be seen in the inset of Fig. 3 . This temperature is near the value of 320 K found with the empirical formula by Tammann: T g = 2/3 T fus . (1)
Specific heats
Using these equations and extrapolating to the melting point of form II at 479.6 K, the relative enthalpies of the liquid and of form II have been calculated as a function of the temperature (Fig. 4) .
Discussion -interpretation of the results through a pressuretemperature phase diagram
Global evaluation of the data and the phase behavior of spironolactone
It is clear from the introduction and the results that the phase behavior of spironolactone is not easy to understand. Based on the present batches from Sanofi and Welding, one can consider that the melting point and melting enthalpy of form II are reasonably correctly defined by the mean values in Table 3 . The temperature of fusion for form I possesses a larger uncertainty, but it can be considered to be in the order of 408 ± 3 K. Obviously, the enthalpy of fusion for form I is experimentally inaccessible as the melting peak and the recrystallization peak are convoluted (Fig. 3) ; however, an estimate of this value will be calculated below in the discussion. Finally, the enthalpy difference between forms I and II is found equal to −6.9 ± 0.3 J g −1 , although in terms of accuracy, it is probably in the order of −6.9 ± 1 J g −1 .
Before constructing the topological phase diagram, the phase behavior will be evaluated using the Le Chatelier principle. The behavior of spironolactone in relation to the pressure can be deduced from the specific volumes of the two polymorphs (see introduction and ). Form I is the denser polymorph and therefore its relative stability will increase with pressure, whereas the relative stability of form II will decrease. It implies that if a phase equilibrium exists, form I will be stable at the high-pressure side and form II at the low-pressure side. A similar analysis can be carried out in terms of the enthalpy of form I and form II. The data from Tables 3 and 4 indicate beyond reasonable doubt that form I possesses a higher absolute enthalpy than form II, which implies that form I is the high temperature form. Interestingly, it is form II that has the highest melting point and this leads to the immediate conclusion that any equilibrium between forms I and II will be located at a higher temperature than the melting point of form II and thus this equilibrium will be metastable under normal pressure. Hence, without any mathematical calculation, it can be concluded that to accommodate the density and enthalpy requirements of the system, I.B. Rietveld et al. International Journal of Pharmaceutics 552 (2018) 193-205 the I-II phase equilibrium line necessarily possesses a negative slope (see Fig. 5 ) with form I stable above the equilibrium and form II below. Furthermore, it can be stated that this I-II phase equilibrium is located at positive pressures (P ≫ 0 MPa) to accommodate for the fact that form II exhibits the stable melting temperature. Finally, this leads to the conclusion that form II is the only stable form under ordinary conditions, i.e. the equilibrium between form II and the vapor phase is stable from 0 K up to its melting point (see Fig. 5 ). This result implies that unless the data in the Tables 3 and 4 are substantially wrong, any calculated phase diagram must obey the overall layout dictated by the Le Chatelier principle as depicted in Fig. 5 .
An equation describing the II-L equilibrium
A mathematical expression for a two-phase equilibrium line can be obtained by using the Clapeyron equation and as the simplest expression for a monotonic function , a straight line can be used. The melting point of form II is the best-documented phase transition in the spironolactone system and the one that most of the literature data seem to agree upon. The data in Table 3 will be used, which is similar to the data in the literature discussed in the introduction. To calculate the slope of the II-L equilibrium with the Clapeyron equation, the volume change on melting is needed too, however, slow decomposition of spironolactone in the molten state prevented the direct measurement of the specific volume of the liquid, which necessitates high temperatures for considerable amounts of time. Nevertheless, several authors have reported mean values for the volume change on melting for organic molecular compounds. Ubbelohde found that the volume increase on melting ranges from 7 to 16% with a mean value of 11.5%, a volume increase that has been confirmed by Gavezzotti (Gavezzotti, 2013; Ubbelohde, 1965) . This value is very close to the value of 12% proposed by Goodman et al. and to the mean value of 10% found within 6 and 17% for several molecular solids of pharmaceutical interest Goodman et al., 2004; Rietveld and Céolin, 2015) . It can be concluded that as an approximation, the volume change on melting of the highest melting polymorph can be taken as 11% of its specific volume.
The specific volume of polymorph II at its melting point of 479.6 K can be calculated using data from Espeau et al. , and the melting temperature, the slope in the pressure-temperature plane, dP/dT, for the two-phase equilibrium II-L can be calculated resulting in 1.23 MPa K −1 . Using P = 0 MPa at T II→L = 479.6 K, because the vapor pressure at the melting point is necessarily smaller than 1 atm (= 0.1 MPa), one can obtain a linear expression for the equilibrium between form II and the liquid as a function of pressure and temperature:
An equation describing the I-L equilibrium
To formulate a mathematical description for the I-L equilibrium line, its equilibrium temperature, the enthalpy change on melting and the volume change on melting are needed for the Clapeyron equation. The equilibrium temperature is the melting point reported in Table 3 . The enthalpy change on melting or the heat of fusion will have to be calculated, making use of the heat capacity Eqs. (1) and (2). In addition, for the volume change on melting, the specific volume of the melt needs to be determined. These two inequalities between form I and the liquid, Δ I→L H and Δ I→L v, will be calculated below using a few approximations. Obviously, approximations will increase the incertitude over the accuracy of the final expression. Nonetheless, considering Fig. 5 , it is clear that the resulting expression for the I-L equilibrium should meet the II-L equilibrium at high pressure, because that is where the I-II and II-L equilibria meet (Fig. 5) . The intersection of I-II and II-L will result in the triple point I-II-L and this triple point is part of the I-L equilibrium too. It implies that the Clapeyron equation must result in a slope dP/ dT < 1.23 MPa K −1 , the slope of the II-L equilibrium.
Heat of fusion of form I
The heat of fusion of form I can only be determined indirectly, because of the immediate recrystallization of its melt into form II (Sanofi sample) or its direct transformation into form II (Welding sample). It necessitates the use of the specific heats as provided by Eqs. (1) and (2). First, the heat of fusion of form II is obtained at the melting point of form I, using the Kirchhoff equation:
is the change in the difference in enthalpy between form II and the liquid when going from the melting point of form II (T II→L ) to the melting point of form I (T I→L ). Using the data from Table 3 , the respective melting points are T II→L = 479.6 K and T I→L = 408 K. The change in the enthalpy using Eqs. (1) and (2) The enthalpy of fusion of form I, ΔH I→L , can be found using the property of a function of state that its value is only determined by the initial and final conditions and the path does not affect its value: ΔH I→L = ΔH I→II + ΔH II→L and thus ΔH I→L = (−6.9) + 46.5 = 39.6 J g −1 .
The enthalpy change between form I and form II, ΔH I→II , is here taken as −6.9 J g −1 (Table 4) , as the change in the difference in the specific heat between the two solids is expected to be small and T I→II and T I→L are relatively close. Tables 1 and 2 . Arrow "a" represents the transformation of form II into the denser form I on increasing pressure and arrow "b" represents the endothermic transformation of form II into form I, which possesses the higher absolute enthalpy. The phase equilibrium between forms I and II must have a negative slope to accommodate a high-pressure, high-temperature phase I and a low-temperature, low-pressure phase II. As a result, form II is the only stable phase under ordinary conditions, i.e. the solid II -vapor equilibrium, up to its melting point (solid black circle). Solid lines: stable phase equilibria, dashed lines: metastable phase equilibria. I.B. Rietveld et al. International Journal of Pharmaceutics 552 (2018) 193-205 
Specific volume of the liquid as a function of the temperature
The specific volume of the melt at the melting point of form I is necessary to calculate the change in the specific volume on the melting of form I. Sufficiently far from the critical point, the temperature dependence of v L is usually described by a straight line:
·T with v 0 the specific volume at T = 0 K and a v,L a measure for the slope relative to v 0 . In the case of spironolactone, an approximation for this expression can be obtained by using the volume of the liquid at the melting point of form II (see the discussion above on the slope of the II-L equilibrium line) and statistical information on the difference in the specific volume between its glass and its crystalline solid at the glass transition temperature (T g ), the former being 6% larger. Very few data are available in the literature, however, a few glass -crystal volume differences obtained from experiment have been recently reported for a number of pharmaceuticals (see Table 5 ).
There is a large spread in the glass transition temperatures obtained for spironolactone. In the literature, values of 331 K (Fukuoka et al., 1991) and 364 K (Mahlin and Bergstrom, 2013) have been found, whereas in the present experiments T g was found to be 306 K. Because the latter value was obtained together with the other data in Table 1 that have been used for the calculations, 306 K, will be used. For a higher T g , the slope of the specific volume of the liquid, dv L /dT, will be steeper and the specific volume of liquid spironolactone will be somewhat smaller at the melting point of form I, thus decreasing the volume difference between the solid and the liquid. Because the volume difference is found in the denominator of the Clapeyron equation, a smaller difference will make the slope of the I-L phase equilibrium steeper. Following the arguments in the first section of the discussion, the slope can never be larger than 1.23 MPa K −1 , as in that case the two phase equilibria I-L and II-L will intersect at negative pressure and that would invalidate the rather basic observations on which the phase diagram in Fig. 5 is based. The specific volume of the melt at T II→L is 0.9203 cm 3 g −1 as determined above. If the specific volume of the glass at T g is 6% larger than the stable crystalline form, it can be calculated evaluating the specific volume of form II , which is indeed smaller than the slope of equilibrium II-L confirming that the two equilibria converge on increasing pressure and temperature. Setting the pressure P equal to 0 MPa at T I→L , a linear expression of the I-L equilibrium can be obtained:
Using Eqs. (3) and (6), the triple point coordinates of I-II-L are found to be T I-II-L = 1094 K and P I-II-L = 758 MPa.
In the case that 364 K is used as the glass transition temperature, which is the highest value found in the literature (Mahlin and Bergstrom, 2013) , it would result in an expression for the I-L equilibrium of P /MPa= 1.23 T /K − 500 and the triple point would be found at T = 9875 K and P = 11600 MPa. This is obviously much larger than the triple point coordinates calculated with Eq. (6), because for T g = 364 K, the slope of the I-L equation becomes only a fraction smaller than the slope of II-L; nonetheless, it does not invalidate the schematic phase diagram based on the principle of Le Chatelier in Fig. 5. 
An equation for the I-II equilibrium line
As concluded in Section 4.1, the slope dP/dT of the I-II equilibrium line is negative with form I stable above and on the right-hand side of the equilibrium line and form II stable below the equilibrium line and on its left-hand side. Because the triple point I-II-L obtained with Eqs. (3) and (6) is rather high in pressure and temperature, it is not possible to obtain reliable calorimetric data on the I-II slope. A simple estimate can be obtained by considering that the enthalpy of transition Δ I→II H = −6.9 J g −1 . This enthalpy has been obtained at a temperature of 375 K, hence an estimate of the entropy involved is −0.018 J g 
With this last equation, the complete topological phase diagram of the two solid phases of spironolactone can be described (Fig. 6) .
Concluding remarks
The topological pressure-temperature phase diagram of spironolactone describing the phase relationships between forms I and II of spironolactone is presented in Fig. 6 . As stated in the beginning of the discussion, the I-II equilibrium line is located at high pressure. The only stable phase of importance for drug formulations is form II, which is Table 5 Volume changes of pharmaceuticals at melting points and glass transition temperatures obtained from experiment. I.B. Rietveld et al. International Journal of Pharmaceutics 552 (2018) 193-205 stable over the entire temperature range under ordinary pressure (solid line c -1 in Fig. 6 ). The phase diagram in Fig. 6 has not been easily obtained, because the transformation of form I into form II through the liquid phase was difficult to interpret with a previous publication reporting a difference in enthalpy between the two polymorphs in the order of 0 J g −1 . In the present paper, the observation of a direct transformation of form I into form II without an intermediate liquid phase made it possible to conclude that the enthalpy change is negative for the I → II transformation. Another difficulty is the wide range of observed glass transition temperatures, which still lacks a clear explanation.
Despite of the difficulties in obtaining reliable data, the topological phase diagram as represented in Fig. 6 has been confirmed in two ways. Firstly, the obtention of the negative enthalpy difference for the transformation of form I into form II and the specific volume data of the two solid forms have led unequivocally to the schematic phase diagram in Fig. 5 . Secondly, the calculations using the Clapeyron equation demonstrating the intersection of the two solid -liquid equilibria at high pressure and temperature confirm the topological result obtained through the Le Chatelier principle. Unfortunately, the experimental data on the melting equilibrium of form I and the metastable I-II transition is not precise enough to accurately define the I-II-L triple point, which remains an estimate. Subsequently, the I-II equation, which depends on the location of the I-II-L triple point, can only be tentatively described, even if it is clear that its slope is negative.
An exothermic transformation of one solid form into another has previously been observed for biclotymol, however in that case the two melting equilibria diverge and only a single stable polymorph exists: overall monotropy (Ceolin et al., 2008) . The phase diagram of spironolactone is surprisingly similar to that of paracetamol, with one form metastable under ordinary conditions, but stable under pressure (Barrio et al., 2017b; Espeau et al., 2005; Ledru et al., 2007) . Furthermore, the solid-solid equilibrium line is also negative for paracetamol (Barrio et al., 2017b; Espeau et al., 2005; Ledru et al., 2007) . In more general terms, the phase diagram of spironolactone belongs to the third case among the four possible cases of dimorphism described by BakhuisRoozeboom (Bakhuis Roozeboom, 1901) .
The experimental difficulties notwithstanding, spironolactone is interesting due to the extremely rare difference of seventy degrees between the melting points of its two polymorphs as can be concluded from the data compiled by Burger and Ramberger (Burger and Ramberger, 1979b) and from more recently obtained data (Table 1) . It is unexpected that the lower melting polymorph actually possesses a stable domain in the pressure-temperature phase diagram, because it goes against the rule of thumb that the densest form is also the most stable. Taking into consideration the shallowness of the slopes of the two melting equilibria and the fact that they are very similar, one must conclude that the Gibbs free energy surfaces of the two polymorphs are most likely rather close to each other despite the large difference in melting points. The closeness in Gibbs free energy can also be inferred from the observation that form I shows little tendency to transform into form II and thus that a strong driving force for this transition is lacking. This is validated by the fact that both polymorphs do not contain hydrogen bonds and thus that the main interactions involve only Van der Waals forces and thus no strong energy barriers are expected that restrict phase transformations.
